Lindahl acts as legal advisor when Swedencare AB (publ) acquires the business conducted by US animal health company Stratford Pharmaceuticals, LLC. The acquisition is structured as a business transfer and is made by a newly established US subsidiary to Swedencare. The purchase price amounts to approximately USD 17 million, corresponding to almost 160 million SEK. As part of the financing of the acquisition, Swedencare also carried out a directed share issue of 1,500,000 shares to institutional investors. The share issue has provided the company with gross proceeds of approximately SEK 133 million.
Swedencare develops, produces, markets, and sells premium products on the global and fast-growing market for animal health products for cats, dogs and horses. The company’s product groups are represented on approximately fifty markets around the world and are sold through subsidiaries in the Nordics, United States, France, Spain, Greece, Great Britain and Ireland and through an external distribution network. Swedencare’s share is listed on Nasdaq First North Growth Market with ticker SECARE.
Stratford Pharmaceuticals has been operating on the US veterinary market since 2011. Stratford Pharmaceuticals has a broad product portfolio in a variety of therapeutic areas for dogs and cats. Applying a multi-channel strategy, sales are made to 10,000 veterinary clinics, large purchasing organizations and e-commerce players.
Lindahl’s team consisted of Johan Herrström, Carl-Johan Krusell, Pernilla Skoglösa and Axel Strandborg. Lindahl was assisted in the acquisition by Wiggin and Dana in New York, a member of the same global network as Lindahl, TerraLex.
